nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—CYP1A2—Carmustine—malignant glioma	0.273	1	CbGbCtD
Leflunomide—Traumatic liver injury—Temozolomide—malignant glioma	0.00843	0.0267	CcSEcCtD
Leflunomide—Opportunistic infection—Temozolomide—malignant glioma	0.0078	0.0247	CcSEcCtD
Leflunomide—Pulmonary fibrosis—Carmustine—malignant glioma	0.00739	0.0234	CcSEcCtD
Leflunomide—Pulmonary fibrosis—Temozolomide—malignant glioma	0.00714	0.0226	CcSEcCtD
Leflunomide—Interstitial pneumonia—Temozolomide—malignant glioma	0.0065	0.0206	CcSEcCtD
Leflunomide—Niflumic Acid—PTGS1—malignant glioma	0.00603	0.636	CrCbGaD
Leflunomide—Oral candidiasis—Carmustine—malignant glioma	0.00512	0.0162	CcSEcCtD
Leflunomide—Oral candidiasis—Temozolomide—malignant glioma	0.00494	0.0157	CcSEcCtD
Leflunomide—Cyst—Carmustine—malignant glioma	0.00486	0.0154	CcSEcCtD
Leflunomide—Tooth disorder—Temozolomide—malignant glioma	0.00484	0.0153	CcSEcCtD
Leflunomide—Digestion impaired—Temozolomide—malignant glioma	0.0047	0.0149	CcSEcCtD
Leflunomide—Interstitial lung disease—Carmustine—malignant glioma	0.00459	0.0145	CcSEcCtD
Leflunomide—Interstitial lung disease—Temozolomide—malignant glioma	0.00444	0.014	CcSEcCtD
Leflunomide—Hepatotoxicity—Carmustine—malignant glioma	0.00421	0.0133	CcSEcCtD
Leflunomide—Herpes zoster—Temozolomide—malignant glioma	0.00417	0.0132	CcSEcCtD
Leflunomide—Cholestasis—Temozolomide—malignant glioma	0.00414	0.0131	CcSEcCtD
Leflunomide—Abscess—Carmustine—malignant glioma	0.00411	0.013	CcSEcCtD
Leflunomide—Hepatotoxicity—Temozolomide—malignant glioma	0.00407	0.0129	CcSEcCtD
Leflunomide—Endocrine disorder—Temozolomide—malignant glioma	0.00379	0.012	CcSEcCtD
Leflunomide—Liver injury—Temozolomide—malignant glioma	0.00373	0.0118	CcSEcCtD
Leflunomide—PTK2B—embryo—malignant glioma	0.00364	0.132	CbGeAlD
Leflunomide—Niflumic Acid—PTGS2—malignant glioma	0.00344	0.364	CrCbGaD
Leflunomide—Herpes simplex—Temozolomide—malignant glioma	0.00341	0.0108	CcSEcCtD
Leflunomide—Hepatic enzyme increased—Temozolomide—malignant glioma	0.00332	0.0105	CcSEcCtD
Leflunomide—Neck pain—Carmustine—malignant glioma	0.00329	0.0104	CcSEcCtD
Leflunomide—Candida infection—Carmustine—malignant glioma	0.0031	0.00982	CcSEcCtD
Leflunomide—Candida infection—Temozolomide—malignant glioma	0.003	0.00949	CcSEcCtD
Leflunomide—PTK2B—telencephalon—malignant glioma	0.00296	0.107	CbGeAlD
Leflunomide—Neoplasm—Carmustine—malignant glioma	0.00294	0.0093	CcSEcCtD
Leflunomide—Neoplasm—Temozolomide—malignant glioma	0.00284	0.00899	CcSEcCtD
Leflunomide—Sepsis—Carmustine—malignant glioma	0.00282	0.00893	CcSEcCtD
Leflunomide—Diabetes mellitus—Carmustine—malignant glioma	0.00271	0.00859	CcSEcCtD
Leflunomide—Gastroenteritis—Temozolomide—malignant glioma	0.00257	0.00814	CcSEcCtD
Leflunomide—Hepatic failure—Temozolomide—malignant glioma	0.00254	0.00803	CcSEcCtD
Leflunomide—AHR—telencephalon—malignant glioma	0.00243	0.0882	CbGeAlD
Leflunomide—Liver function test abnormal—Carmustine—malignant glioma	0.00218	0.0069	CcSEcCtD
Leflunomide—Hypokalaemia—Carmustine—malignant glioma	0.00215	0.0068	CcSEcCtD
Leflunomide—DHODH—brain—malignant glioma	0.00211	0.0764	CbGeAlD
Leflunomide—Dry skin—Temozolomide—malignant glioma	0.00209	0.00662	CcSEcCtD
Leflunomide—Hypokalaemia—Temozolomide—malignant glioma	0.00208	0.00657	CcSEcCtD
Leflunomide—Breast disorder—Temozolomide—malignant glioma	0.00206	0.00652	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.00205	0.0065	CcSEcCtD
Leflunomide—Pancytopenia—Carmustine—malignant glioma	0.00194	0.00613	CcSEcCtD
Leflunomide—Sweating increased—Temozolomide—malignant glioma	0.00192	0.00608	CcSEcCtD
Leflunomide—AHR—medulla oblongata—malignant glioma	0.00191	0.0693	CbGeAlD
Leflunomide—Neutropenia—Carmustine—malignant glioma	0.00191	0.00604	CcSEcCtD
Leflunomide—Bronchitis—Temozolomide—malignant glioma	0.0019	0.006	CcSEcCtD
Leflunomide—Pancytopenia—Temozolomide—malignant glioma	0.00187	0.00592	CcSEcCtD
Leflunomide—Neutropenia—Temozolomide—malignant glioma	0.00184	0.00583	CcSEcCtD
Leflunomide—Dysuria—Temozolomide—malignant glioma	0.00184	0.00583	CcSEcCtD
Leflunomide—Hyperglycaemia—Carmustine—malignant glioma	0.00184	0.00582	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00183	0.0058	CcSEcCtD
Leflunomide—Pneumonia—Carmustine—malignant glioma	0.00183	0.00579	CcSEcCtD
Leflunomide—Pollakiuria—Temozolomide—malignant glioma	0.00182	0.00576	CcSEcCtD
Leflunomide—Renal failure—Carmustine—malignant glioma	0.00179	0.00566	CcSEcCtD
Leflunomide—Weight decreased—Temozolomide—malignant glioma	0.00178	0.00564	CcSEcCtD
Leflunomide—Neuropathy peripheral—Carmustine—malignant glioma	0.00178	0.00564	CcSEcCtD
Leflunomide—Hyperglycaemia—Temozolomide—malignant glioma	0.00178	0.00563	CcSEcCtD
Leflunomide—Stomatitis—Carmustine—malignant glioma	0.00177	0.00561	CcSEcCtD
Leflunomide—Urinary tract infection—Carmustine—malignant glioma	0.00177	0.00559	CcSEcCtD
Leflunomide—Pneumonia—Temozolomide—malignant glioma	0.00177	0.00559	CcSEcCtD
Leflunomide—Infestation NOS—Temozolomide—malignant glioma	0.00176	0.00556	CcSEcCtD
Leflunomide—Infestation—Temozolomide—malignant glioma	0.00176	0.00556	CcSEcCtD
Leflunomide—AHR—midbrain—malignant glioma	0.00175	0.0633	CbGeAlD
Leflunomide—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.00174	0.00551	CcSEcCtD
Leflunomide—Neuropathy peripheral—Temozolomide—malignant glioma	0.00172	0.00545	CcSEcCtD
Leflunomide—Stomatitis—Temozolomide—malignant glioma	0.00171	0.00542	CcSEcCtD
Leflunomide—Urinary tract infection—Temozolomide—malignant glioma	0.00171	0.00541	CcSEcCtD
Leflunomide—AHR—spinal cord—malignant glioma	0.0017	0.0618	CbGeAlD
Leflunomide—PTK2B—central nervous system—malignant glioma	0.00168	0.061	CbGeAlD
Leflunomide—Hepatobiliary disease—Temozolomide—malignant glioma	0.00166	0.00526	CcSEcCtD
Leflunomide—Sinusitis—Temozolomide—malignant glioma	0.00165	0.00522	CcSEcCtD
Leflunomide—PTK2B—cerebellum—malignant glioma	0.00164	0.0596	CbGeAlD
Leflunomide—Haemoglobin—Carmustine—malignant glioma	0.00164	0.00519	CcSEcCtD
Leflunomide—Haemorrhage—Carmustine—malignant glioma	0.00163	0.00517	CcSEcCtD
Leflunomide—Oedema peripheral—Carmustine—malignant glioma	0.00161	0.00509	CcSEcCtD
Leflunomide—Connective tissue disorder—Carmustine—malignant glioma	0.0016	0.00508	CcSEcCtD
Leflunomide—Haemoglobin—Temozolomide—malignant glioma	0.00159	0.00502	CcSEcCtD
Leflunomide—Hepatitis—Temozolomide—malignant glioma	0.00158	0.00499	CcSEcCtD
Leflunomide—Haemorrhage—Temozolomide—malignant glioma	0.00158	0.00499	CcSEcCtD
Leflunomide—Pharyngitis—Temozolomide—malignant glioma	0.00157	0.00496	CcSEcCtD
Leflunomide—Urinary tract disorder—Temozolomide—malignant glioma	0.00156	0.00493	CcSEcCtD
Leflunomide—Oedema peripheral—Temozolomide—malignant glioma	0.00155	0.00492	CcSEcCtD
Leflunomide—Connective tissue disorder—Temozolomide—malignant glioma	0.00155	0.00491	CcSEcCtD
Leflunomide—Urethral disorder—Temozolomide—malignant glioma	0.00155	0.00489	CcSEcCtD
Leflunomide—Eye disorder—Carmustine—malignant glioma	0.00153	0.00483	CcSEcCtD
Leflunomide—Erythema multiforme—Temozolomide—malignant glioma	0.00149	0.00472	CcSEcCtD
Leflunomide—Eye disorder—Temozolomide—malignant glioma	0.00147	0.00467	CcSEcCtD
Leflunomide—Cardiac disorder—Temozolomide—malignant glioma	0.00146	0.00463	CcSEcCtD
Leflunomide—Arrhythmia—Carmustine—malignant glioma	0.00146	0.00462	CcSEcCtD
Leflunomide—Alopecia—Carmustine—malignant glioma	0.00144	0.00457	CcSEcCtD
Leflunomide—Mental disorder—Carmustine—malignant glioma	0.00143	0.00453	CcSEcCtD
Leflunomide—Immune system disorder—Temozolomide—malignant glioma	0.00142	0.00451	CcSEcCtD
Leflunomide—Mediastinal disorder—Temozolomide—malignant glioma	0.00142	0.0045	CcSEcCtD
Leflunomide—Malnutrition—Carmustine—malignant glioma	0.00142	0.0045	CcSEcCtD
Leflunomide—Chills—Temozolomide—malignant glioma	0.00142	0.00448	CcSEcCtD
Leflunomide—Alopecia—Temozolomide—malignant glioma	0.00139	0.00441	CcSEcCtD
Leflunomide—Mental disorder—Temozolomide—malignant glioma	0.00138	0.00437	CcSEcCtD
Leflunomide—Back pain—Carmustine—malignant glioma	0.00137	0.00435	CcSEcCtD
Leflunomide—Malnutrition—Temozolomide—malignant glioma	0.00137	0.00435	CcSEcCtD
Leflunomide—AHR—cerebellum—malignant glioma	0.00135	0.049	CbGeAlD
Leflunomide—Dysgeusia—Temozolomide—malignant glioma	0.00134	0.00426	CcSEcCtD
Leflunomide—Vision blurred—Carmustine—malignant glioma	0.00134	0.00424	CcSEcCtD
Leflunomide—PTK2B—brain—malignant glioma	0.00134	0.0484	CbGeAlD
Leflunomide—Back pain—Temozolomide—malignant glioma	0.00133	0.0042	CcSEcCtD
Leflunomide—Anaemia—Carmustine—malignant glioma	0.00131	0.00416	CcSEcCtD
Leflunomide—Vision blurred—Temozolomide—malignant glioma	0.00129	0.0041	CcSEcCtD
Leflunomide—Ill-defined disorder—Temozolomide—malignant glioma	0.00127	0.00403	CcSEcCtD
Leflunomide—Leukopenia—Carmustine—malignant glioma	0.00127	0.00403	CcSEcCtD
Leflunomide—Anaemia—Temozolomide—malignant glioma	0.00127	0.00402	CcSEcCtD
Leflunomide—Angioedema—Temozolomide—malignant glioma	0.00125	0.00397	CcSEcCtD
Leflunomide—Malaise—Temozolomide—malignant glioma	0.00124	0.00392	CcSEcCtD
Leflunomide—Vertigo—Temozolomide—malignant glioma	0.00123	0.00391	CcSEcCtD
Leflunomide—Leukopenia—Temozolomide—malignant glioma	0.00123	0.00389	CcSEcCtD
Leflunomide—Hypertension—Carmustine—malignant glioma	0.00123	0.00388	CcSEcCtD
Leflunomide—Palpitations—Temozolomide—malignant glioma	0.00121	0.00384	CcSEcCtD
Leflunomide—Chest pain—Carmustine—malignant glioma	0.00121	0.00383	CcSEcCtD
Leflunomide—Myalgia—Carmustine—malignant glioma	0.00121	0.00383	CcSEcCtD
Leflunomide—Anxiety—Carmustine—malignant glioma	0.00121	0.00382	CcSEcCtD
Leflunomide—Cough—Temozolomide—malignant glioma	0.0012	0.00379	CcSEcCtD
Leflunomide—Hypertension—Temozolomide—malignant glioma	0.00119	0.00375	CcSEcCtD
Leflunomide—Myalgia—Temozolomide—malignant glioma	0.00117	0.0037	CcSEcCtD
Leflunomide—Arthralgia—Temozolomide—malignant glioma	0.00117	0.0037	CcSEcCtD
Leflunomide—Anxiety—Temozolomide—malignant glioma	0.00117	0.00369	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00116	0.00368	CcSEcCtD
Leflunomide—Discomfort—Temozolomide—malignant glioma	0.00116	0.00366	CcSEcCtD
Leflunomide—Infection—Carmustine—malignant glioma	0.00115	0.00365	CcSEcCtD
Leflunomide—Dry mouth—Temozolomide—malignant glioma	0.00114	0.00362	CcSEcCtD
Leflunomide—Thrombocytopenia—Carmustine—malignant glioma	0.00114	0.00359	CcSEcCtD
Leflunomide—Tachycardia—Carmustine—malignant glioma	0.00113	0.00358	CcSEcCtD
Leflunomide—Anaphylactic shock—Temozolomide—malignant glioma	0.00112	0.00355	CcSEcCtD
Leflunomide—Infection—Temozolomide—malignant glioma	0.00111	0.00352	CcSEcCtD
Leflunomide—Anorexia—Carmustine—malignant glioma	0.00111	0.0035	CcSEcCtD
Leflunomide—Nervous system disorder—Temozolomide—malignant glioma	0.0011	0.00348	CcSEcCtD
Leflunomide—AHR—brain—malignant glioma	0.0011	0.0398	CbGeAlD
Leflunomide—Thrombocytopenia—Temozolomide—malignant glioma	0.0011	0.00347	CcSEcCtD
Leflunomide—Skin disorder—Temozolomide—malignant glioma	0.00109	0.00345	CcSEcCtD
Leflunomide—Hypotension—Carmustine—malignant glioma	0.00108	0.00343	CcSEcCtD
Leflunomide—Hyperhidrosis—Temozolomide—malignant glioma	0.00108	0.00343	CcSEcCtD
Leflunomide—Anorexia—Temozolomide—malignant glioma	0.00107	0.00338	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00106	0.00334	CcSEcCtD
Leflunomide—Insomnia—Carmustine—malignant glioma	0.00105	0.00332	CcSEcCtD
Leflunomide—Paraesthesia—Carmustine—malignant glioma	0.00104	0.0033	CcSEcCtD
Leflunomide—Dyspnoea—Carmustine—malignant glioma	0.00103	0.00327	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00102	0.00323	CcSEcCtD
Leflunomide—Insomnia—Temozolomide—malignant glioma	0.00101	0.00321	CcSEcCtD
Leflunomide—Decreased appetite—Carmustine—malignant glioma	0.00101	0.00319	CcSEcCtD
Leflunomide—Paraesthesia—Temozolomide—malignant glioma	0.00101	0.00319	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Carmustine—malignant glioma	0.001	0.00317	CcSEcCtD
Leflunomide—Dyspnoea—Temozolomide—malignant glioma	0.000999	0.00316	CcSEcCtD
Leflunomide—Constipation—Carmustine—malignant glioma	0.000992	0.00314	CcSEcCtD
Leflunomide—Pain—Carmustine—malignant glioma	0.000992	0.00314	CcSEcCtD
Leflunomide—Dyspepsia—Temozolomide—malignant glioma	0.000986	0.00312	CcSEcCtD
Leflunomide—Decreased appetite—Temozolomide—malignant glioma	0.000974	0.00308	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000968	0.00306	CcSEcCtD
Leflunomide—Fatigue—Temozolomide—malignant glioma	0.000966	0.00306	CcSEcCtD
Leflunomide—Constipation—Temozolomide—malignant glioma	0.000958	0.00303	CcSEcCtD
Leflunomide—Pain—Temozolomide—malignant glioma	0.000958	0.00303	CcSEcCtD
Leflunomide—Feeling abnormal—Carmustine—malignant glioma	0.000956	0.00303	CcSEcCtD
Leflunomide—Gastrointestinal pain—Carmustine—malignant glioma	0.000948	0.003	CcSEcCtD
Leflunomide—ABCG2—telencephalon—malignant glioma	0.000943	0.0342	CbGeAlD
Leflunomide—Feeling abnormal—Temozolomide—malignant glioma	0.000924	0.00292	CcSEcCtD
Leflunomide—Body temperature increased—Carmustine—malignant glioma	0.000917	0.0029	CcSEcCtD
Leflunomide—Abdominal pain—Carmustine—malignant glioma	0.000917	0.0029	CcSEcCtD
Leflunomide—Gastrointestinal pain—Temozolomide—malignant glioma	0.000916	0.0029	CcSEcCtD
Leflunomide—Urticaria—Temozolomide—malignant glioma	0.00089	0.00282	CcSEcCtD
Leflunomide—Abdominal pain—Temozolomide—malignant glioma	0.000886	0.0028	CcSEcCtD
Leflunomide—Body temperature increased—Temozolomide—malignant glioma	0.000886	0.0028	CcSEcCtD
Leflunomide—Hypersensitivity—Carmustine—malignant glioma	0.000854	0.0027	CcSEcCtD
Leflunomide—Asthenia—Carmustine—malignant glioma	0.000832	0.00263	CcSEcCtD
Leflunomide—Hypersensitivity—Temozolomide—malignant glioma	0.000826	0.00261	CcSEcCtD
Leflunomide—Asthenia—Temozolomide—malignant glioma	0.000804	0.00255	CcSEcCtD
Leflunomide—Diarrhoea—Carmustine—malignant glioma	0.000793	0.00251	CcSEcCtD
Leflunomide—Pruritus—Temozolomide—malignant glioma	0.000793	0.00251	CcSEcCtD
Leflunomide—Dizziness—Carmustine—malignant glioma	0.000767	0.00243	CcSEcCtD
Leflunomide—Diarrhoea—Temozolomide—malignant glioma	0.000767	0.00243	CcSEcCtD
Leflunomide—ABCG2—medulla oblongata—malignant glioma	0.000741	0.0269	CbGeAlD
Leflunomide—Dizziness—Temozolomide—malignant glioma	0.000741	0.00235	CcSEcCtD
Leflunomide—Vomiting—Carmustine—malignant glioma	0.000737	0.00233	CcSEcCtD
Leflunomide—Rash—Carmustine—malignant glioma	0.000731	0.00231	CcSEcCtD
Leflunomide—Dermatitis—Carmustine—malignant glioma	0.000731	0.00231	CcSEcCtD
Leflunomide—Headache—Carmustine—malignant glioma	0.000726	0.0023	CcSEcCtD
Leflunomide—Vomiting—Temozolomide—malignant glioma	0.000713	0.00226	CcSEcCtD
Leflunomide—Rash—Temozolomide—malignant glioma	0.000707	0.00224	CcSEcCtD
Leflunomide—Dermatitis—Temozolomide—malignant glioma	0.000706	0.00223	CcSEcCtD
Leflunomide—Headache—Temozolomide—malignant glioma	0.000702	0.00222	CcSEcCtD
Leflunomide—Nausea—Carmustine—malignant glioma	0.000689	0.00218	CcSEcCtD
Leflunomide—ABCG2—midbrain—malignant glioma	0.000677	0.0246	CbGeAlD
Leflunomide—Nausea—Temozolomide—malignant glioma	0.000666	0.00211	CcSEcCtD
Leflunomide—ABCG2—spinal cord—malignant glioma	0.000661	0.024	CbGeAlD
Leflunomide—ABCG2—cerebellum—malignant glioma	0.000524	0.019	CbGeAlD
Leflunomide—ABCG2—brain—malignant glioma	0.000426	0.0154	CbGeAlD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—KRAS—malignant glioma	0.000249	0.000666	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PARK2—malignant glioma	0.000249	0.000666	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—LGALS3—malignant glioma	0.000249	0.000666	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—RAF1—malignant glioma	0.000248	0.000664	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—AKT1—malignant glioma	0.000246	0.000658	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—CYP2C18—malignant glioma	0.000245	0.000655	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PIK3CB—malignant glioma	0.000242	0.000648	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP2C18—malignant glioma	0.000242	0.000646	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—DTX1—malignant glioma	0.00024	0.000643	CbGpPWpGaD
Leflunomide—CYP1A2—Phase II conjugation—GSTP1—malignant glioma	0.000235	0.000628	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—GSTT1—malignant glioma	0.000232	0.00062	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PIK3CG—malignant glioma	0.00023	0.000614	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PML—malignant glioma	0.000224	0.000598	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-C—malignant glioma	0.000224	0.000598	CbGpPWpGaD
Leflunomide—CYP2C9—Arachidonic acid metabolism—PTGS2—malignant glioma	0.000224	0.000598	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL1B—malignant glioma	0.000223	0.000597	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL2—malignant glioma	0.000223	0.000595	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PPARG—malignant glioma	0.000222	0.000592	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—PTGS1—malignant glioma	0.000217	0.000581	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—malignant glioma	0.000213	0.00057	CbGpPWpGaD
Leflunomide—CYP1A2—Tryptophan metabolism—MDM2—malignant glioma	0.000212	0.000567	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—malignant glioma	0.000211	0.000565	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CTSB—malignant glioma	0.000208	0.000556	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—AKT1—malignant glioma	0.000205	0.000549	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—malignant glioma	0.000204	0.000547	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PIK3CD—malignant glioma	0.000202	0.00054	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—GSTT1—malignant glioma	0.000198	0.00053	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—DUSP6—malignant glioma	0.000194	0.000518	CbGpPWpGaD
Leflunomide—CYP1A2—Arachidonic acid metabolism—PTGS2—malignant glioma	0.000191	0.000511	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SUFU—malignant glioma	0.000191	0.00051	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—malignant glioma	0.00019	0.000508	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—malignant glioma	0.000189	0.000507	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HEY2—malignant glioma	0.000189	0.000504	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—STAT3—malignant glioma	0.000187	0.000501	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—FBXW7—malignant glioma	0.000187	0.000501	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—AKT1—malignant glioma	0.000187	0.0005	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—PTGS1—malignant glioma	0.000186	0.000497	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—COX8A—malignant glioma	0.000185	0.000494	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—GFAP—malignant glioma	0.000184	0.000493	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—AKT1—malignant glioma	0.000178	0.000477	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SPHK1—malignant glioma	0.000178	0.000477	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PIK3CB—malignant glioma	0.000176	0.00047	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCR4—malignant glioma	0.000175	0.000467	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HEY1—malignant glioma	0.000175	0.000467	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PTGS2—malignant glioma	0.000174	0.000466	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HIST1H3B—malignant glioma	0.00017	0.000454	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IFNA2—malignant glioma	0.000164	0.000438	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—RTEL1—malignant glioma	0.000162	0.000435	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—malignant glioma	0.000161	0.00043	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—KRAS—malignant glioma	0.000161	0.00043	CbGpPWpGaD
Leflunomide—CYP2C9—Biological oxidations—GSTP1—malignant glioma	0.000161	0.00043	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—GSTP1—malignant glioma	0.000158	0.000424	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ASMT—malignant glioma	0.000157	0.00042	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—TFRC—malignant glioma	0.000157	0.00042	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—JAG2—malignant glioma	0.000155	0.000414	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PTEN—malignant glioma	0.000152	0.000406	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—malignant glioma	0.000148	0.000396	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PIK3CA—malignant glioma	0.000148	0.000395	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—BCAN—malignant glioma	0.000148	0.000395	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—malignant glioma	0.000145	0.000387	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—malignant glioma	0.000145	0.000387	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC5A5—malignant glioma	0.000144	0.000386	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTK2—malignant glioma	0.000142	0.000381	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—RTEL1—malignant glioma	0.000139	0.000371	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—malignant glioma	0.000138	0.000369	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—malignant glioma	0.000138	0.000369	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—GSTP1—malignant glioma	0.000137	0.000367	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC6A3—malignant glioma	0.000137	0.000367	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—malignant glioma	0.000137	0.000366	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—GSTP1—malignant glioma	0.000135	0.000362	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PDGFRA—malignant glioma	0.000133	0.000356	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-B—malignant glioma	0.000132	0.000354	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—H3F3A—malignant glioma	0.000131	0.00035	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCR3—malignant glioma	0.00013	0.000347	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—YWHAE—malignant glioma	0.000126	0.000338	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NTRK2—malignant glioma	0.000126	0.000338	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FLT1—malignant glioma	0.000126	0.000336	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—DUSP6—malignant glioma	0.000125	0.000335	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—JAG1—malignant glioma	0.000124	0.00033	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOTCH3—malignant glioma	0.000123	0.000329	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HLA-A—malignant glioma	0.000123	0.000328	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FBXW7—malignant glioma	0.000121	0.000324	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PDGFB—malignant glioma	0.00012	0.00032	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—IDH2—malignant glioma	0.000119	0.000318	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—FGFR1—malignant glioma	0.000119	0.000318	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—BDKRB2—malignant glioma	0.000119	0.000317	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	0.000116	0.000311	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	0.000112	0.000301	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP2B6—malignant glioma	0.000112	0.000299	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOTCH2—malignant glioma	0.00011	0.000295	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KNG1—malignant glioma	0.000108	0.000289	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PIK3CA—malignant glioma	0.000107	0.000287	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—BAD—malignant glioma	0.000107	0.000285	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD80—malignant glioma	0.000103	0.000277	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NTRK1—malignant glioma	0.000103	0.000275	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—IDH1—malignant glioma	0.000102	0.000274	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGF—malignant glioma	0.000102	0.000273	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTPN11—malignant glioma	0.000101	0.000271	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	9.92e-05	0.000265	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SPHK1—malignant glioma	9.91e-05	0.000265	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP2C18—malignant glioma	9.71e-05	0.00026	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	9.6e-05	0.000257	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP3—malignant glioma	9.57e-05	0.000256	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN2B—malignant glioma	9.48e-05	0.000254	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT2—malignant glioma	9.45e-05	0.000253	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—COX8A—malignant glioma	9.33e-05	0.00025	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTK2—malignant glioma	9.21e-05	0.000246	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CD—malignant glioma	9.08e-05	0.000243	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HES1—malignant glioma	9.05e-05	0.000242	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NCOR1—malignant glioma	8.99e-05	0.000241	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AKT1—malignant glioma	8.76e-05	0.000234	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—FGF2—malignant glioma	8.69e-05	0.000233	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PDGFRA—malignant glioma	8.61e-05	0.00023	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SPP1—malignant glioma	8.36e-05	0.000224	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	8.34e-05	0.000223	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—BCL2—malignant glioma	8.25e-05	0.000221	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IFNG—malignant glioma	8.18e-05	0.000219	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MDM2—malignant glioma	8.13e-05	0.000218	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—RAF1—malignant glioma	8.11e-05	0.000217	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ERBB2—malignant glioma	8.02e-05	0.000214	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—COX8A—malignant glioma	7.97e-05	0.000213	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ASMT—malignant glioma	7.94e-05	0.000212	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TERT—malignant glioma	7.93e-05	0.000212	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CB—malignant glioma	7.91e-05	0.000212	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTT1—malignant glioma	7.85e-05	0.00021	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	7.76e-05	0.000207	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PDGFB—malignant glioma	7.74e-05	0.000207	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FGFR1—malignant glioma	7.7e-05	0.000206	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HIF1A—malignant glioma	7.58e-05	0.000203	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—BCAN—malignant glioma	7.46e-05	0.0002	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS1—malignant glioma	7.36e-05	0.000197	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CAV1—malignant glioma	7.33e-05	0.000196	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL1B—malignant glioma	7.3e-05	0.000195	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL2—malignant glioma	7.27e-05	0.000194	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KDR—malignant glioma	7.25e-05	0.000194	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	7.13e-05	0.000191	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—F2—malignant glioma	6.98e-05	0.000187	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FN1—malignant glioma	6.98e-05	0.000187	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—BAD—malignant glioma	6.89e-05	0.000184	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTEN—malignant glioma	6.84e-05	0.000183	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—BCHE—malignant glioma	6.84e-05	0.000183	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NOTCH1—malignant glioma	6.83e-05	0.000183	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ASMT—malignant glioma	6.78e-05	0.000181	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC5A5—malignant glioma	6.75e-05	0.000181	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CD80—malignant glioma	6.69e-05	0.000179	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CG—malignant glioma	6.68e-05	0.000179	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—APC—malignant glioma	6.68e-05	0.000179	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	6.63e-05	0.000177	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGF—malignant glioma	6.6e-05	0.000177	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTPN11—malignant glioma	6.56e-05	0.000175	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—BCAN—malignant glioma	6.38e-05	0.000171	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—BRAF—malignant glioma	6.28e-05	0.000168	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—RAF1—malignant glioma	6.22e-05	0.000166	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—STAT3—malignant glioma	6.12e-05	0.000164	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT2—malignant glioma	6.11e-05	0.000163	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—IDH2—malignant glioma	6.01e-05	0.000161	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CD—malignant glioma	5.87e-05	0.000157	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	5.67e-05	0.000152	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP2B6—malignant glioma	5.65e-05	0.000151	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FGF2—malignant glioma	5.62e-05	0.00015	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—malignant glioma	5.56e-05	0.000149	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GSTP1—malignant glioma	5.44e-05	0.000146	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CAT—malignant glioma	5.29e-05	0.000142	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MDM2—malignant glioma	5.26e-05	0.000141	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KRAS—malignant glioma	5.25e-05	0.00014	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RAF1—malignant glioma	5.24e-05	0.00014	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ERBB2—malignant glioma	5.18e-05	0.000139	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—IDH1—malignant glioma	5.17e-05	0.000138	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—IDH2—malignant glioma	5.14e-05	0.000137	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CB—malignant glioma	5.12e-05	0.000137	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SPHK1—malignant glioma	5e-05	0.000134	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—NCOR1—malignant glioma	5e-05	0.000134	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL8—malignant glioma	4.92e-05	0.000132	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP2C18—malignant glioma	4.9e-05	0.000131	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	4.85e-05	0.00013	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP2B6—malignant glioma	4.83e-05	0.000129	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CA—malignant glioma	4.82e-05	0.000129	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CASP3—malignant glioma	4.71e-05	0.000126	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL2—malignant glioma	4.7e-05	0.000126	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	4.62e-05	0.000124	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MMP9—malignant glioma	4.45e-05	0.000119	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTEN—malignant glioma	4.42e-05	0.000118	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—IDH1—malignant glioma	4.42e-05	0.000118	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SPHK1—malignant glioma	4.28e-05	0.000114	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	4.21e-05	0.000113	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP2C18—malignant glioma	4.19e-05	0.000112	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CAV1—malignant glioma	4.08e-05	0.000109	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	4.06e-05	0.000109	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—malignant glioma	3.99e-05	0.000107	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTT1—malignant glioma	3.96e-05	0.000106	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—STAT3—malignant glioma	3.95e-05	0.000106	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	3.95e-05	0.000106	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT1—malignant glioma	3.94e-05	0.000105	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS1—malignant glioma	3.72e-05	9.94e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CG—malignant glioma	3.71e-05	9.93e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	3.7e-05	9.9e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—malignant glioma	3.67e-05	9.83e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	3.6e-05	9.62e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—malignant glioma	3.59e-05	9.61e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPARG—malignant glioma	3.58e-05	9.58e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	3.47e-05	9.29e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—BCHE—malignant glioma	3.45e-05	9.24e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC5A5—malignant glioma	3.41e-05	9.12e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KRAS—malignant glioma	3.4e-05	9.08e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTT1—malignant glioma	3.39e-05	9.06e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CD—malignant glioma	3.26e-05	8.73e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	3.23e-05	8.63e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	3.2e-05	8.55e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS1—malignant glioma	3.17e-05	8.49e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	3.16e-05	8.46e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CA—malignant glioma	3.12e-05	8.34e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—malignant glioma	3.02e-05	8.07e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—BCHE—malignant glioma	2.95e-05	7.89e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC5A5—malignant glioma	2.92e-05	7.8e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CB—malignant glioma	2.84e-05	7.61e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—malignant glioma	2.82e-05	7.54e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	2.79e-05	7.46e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	2.76e-05	7.37e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GSTP1—malignant glioma	2.75e-05	7.35e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	2.73e-05	7.31e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CAT—malignant glioma	2.67e-05	7.15e-05	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT1—malignant glioma	2.55e-05	6.82e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NCOR1—malignant glioma	2.53e-05	6.75e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTEN—malignant glioma	2.46e-05	6.57e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	2.38e-05	6.37e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GSTP1—malignant glioma	2.35e-05	6.28e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CAT—malignant glioma	2.29e-05	6.11e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NCOR1—malignant glioma	2.16e-05	5.77e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CAV1—malignant glioma	2.06e-05	5.51e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.97e-05	5.26e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CG—malignant glioma	1.88e-05	5.02e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPARG—malignant glioma	1.81e-05	4.84e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CAV1—malignant glioma	1.76e-05	4.71e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CA—malignant glioma	1.73e-05	4.64e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.68e-05	4.5e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CD—malignant glioma	1.65e-05	4.41e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CG—malignant glioma	1.6e-05	4.29e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPARG—malignant glioma	1.55e-05	4.14e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CB—malignant glioma	1.44e-05	3.84e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—malignant glioma	1.42e-05	3.81e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKT1—malignant glioma	1.42e-05	3.79e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CD—malignant glioma	1.41e-05	3.77e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTEN—malignant glioma	1.24e-05	3.32e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CB—malignant glioma	1.23e-05	3.28e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—malignant glioma	1.22e-05	3.25e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTEN—malignant glioma	1.06e-05	2.84e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CA—malignant glioma	8.76e-06	2.34e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CA—malignant glioma	7.49e-06	2e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKT1—malignant glioma	7.16e-06	1.91e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKT1—malignant glioma	6.11e-06	1.64e-05	CbGpPWpGaD
